License and Collaboration Arrangements (Additional Information) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Zai Lab
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License revenue recognized	$ 6,500		$ 6,500
Zai Lab | Research and Development Support
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future potential milestone payment receivable	91,000		91,000
License revenue recognized	8,000	$ 3,000	8,000	$ 3,000
PAION AG
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future potential milestone payment receivable	109,500		109,500
PAION AG | Cost Reimbursement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues	0	$ 0	0	0
Everest Medicines Limited
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues	1,200		1,800
Sales milestone payments receivable	20,000		$ 20,000
License revenue recognized				8,000
Royalties payable period after first commercial sale of product			10 years
Everest Medicines Limited | Commercial Supply Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues	800		$ 1,700
Percentage of reimbursed for direct and certain indirect manufacturing costs			110.00%
George Washington University
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of royalty payable on net sales			6.00%
Percentage of royalty on payments received from sublicensees			15.00%
Obligation to pay royalties	700		$ 1,400
Harvard University
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of royalty payable on net sales			5.00%
Percentage of royalty on payments received from sublicensees			20.00%
Cost of license revenue	$ 500		$ 1,200	$ 1,600
Clinical development and regulatory milestones amount payable			$ 15,100
Percentage of minimum royalty rate			4.50%
Percentage of maximum royalty based on achievement of annual net product sales thresholds			7.50%
Paratek Pharmaceuticals, Inc.
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of royalty payable on net sales			2.25%
Claim expiration			2023-10
Astrazeneca | Durlobactam
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
One-time Milestone Payment on Net Sales			$ 5,000
Term of Milestone Payment for Net Sales			3 months
Astrazeneca | Zoliflodacin
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
One-time Milestone Payment on Commercial Sales			$ 10,000
Term of Milestone Payment for Commercial Sale			2 years